Elevated reticulocyte count - A clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: A case report

British Journal of Cancer

Volumn 79, Issue 9-10, 1999, Pages 1519-1521

  Serke, S ^a   Riess, H ^a   Oettle, H ^a   Huhn, D ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Gemcitabine; Haemolytic uraemic syndrome (HUS); Pulmonary oedema

Indexed keywords

BLEOMYCIN; CISPLATIN; CYTOTOXIC AGENT; GEMCITABINE; MITOMYCIN C;

ADULT; ARTICLE; BONE MARROW TOXICITY; CASE REPORT; DUODENUM CARCINOMA; HEMODIALYSIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; LUNG EDEMA; MALE; METASTASIS; PANCREAS ADENOCARCINOMA; PAPILLARY CARCINOMA; PLASMAPHERESIS; PRIORITY JOURNAL; RETICULOCYTE COUNT; THROMBOCYTOPENIA; VATER PAPILLA;

EID: 0033015668     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690242     Document Type: Article

References (22)

1. Anderson H, Lund B, Bach F, Thatcher N, Walling J and Hansen HH (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826
2. Brain MC, Dacie JV and Hourihane OB (1962) Microangiopathic hemolytic anemia: the possible role of vascular lesions in pathogenesis. Br J Haematol 8: 358-364
3. Brodowicz T, Breiteneder S, Witschke C and Zielinski CC (1997) Gemcitabine-induced hemolytic uremic syndrome: a case report (letter). J Natl Cancer Inst 89: 1895-1896
4. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B and Tarassoff PG (1994) Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34
5. Conlon PJ, Howell DN, Macik G, Kovalik EC and Smith SR (1995) The renal manifestations and outcome of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in adults. Nephrol Dial Transplant 10: 1189-1193
6. Cortes-Funes H, Martin C, Abratt R and Lund B (1997) Safety profile of gemcitabine, a novel anticancer agent, in non-small-cell lung cancer. Anticancer Drugs 8: 582-587
7. Crocker J and Jones EL (1983) Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma. J Clin Pathol 36: 24
8. DeWit M, Weh HJ and Hossfeld DK (1996) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Med Welt 47: 528-532
9. Dobbie M, Hofer S, Oberholzer M and Herrmann R (1998) Veno-occlusive disease of the liver induced by gemcitabine (letter). Ann Oncol 9: 681
10. Furlan M (1996) Von Willebrand factor: molecular size and functional activity. Ann Hematol 72: 341-348
11. Green MR (1996) Gemicitabine safety overview. Semin Oncol 23(Suppl 10): 32-35
12. Groff JA, Kozak M, Boehmer JP, Demko TM and Diamond JR (1997) Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 29: 280-284
13. Gulati SC, Sordillo P, Kempin S et al (1980) Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. Cancer 45: 2252
14. Keller F, Schwarze H and Schwarz A (1994) Clinical management of hemolyticuremic syndrome and thrombotic-thrombocytopenic purpura. Wien Klin Wochenschr 106: 603-607
15. Kienast J and Schmitz G (1990) Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 75: 116-121
16. Matsumae T, Takebayashi S and Naito S (1996) The clinico-pathological characteristics and outcome in hemolytic-uremic syndrome of adults. Clin Nephrol 45: 153-162
17. Nordstrom B and Strang P (1993) Microangiopathic hemolytic anemias (MAHA) in cancer. A case report and review. Anticancer Res 13: 1845-1850
18. Sens YAS, Miorin LA, Silva HGC, Malheiros DMAC, Filho DM and Jabur P (1997) Acute renal failure due to hemolytic-uremic syndrome in adult patients. Renal Fail 19: 279-282
19. Streiff M and Bell WR (1993) Thrombotic thrombocytopenic purpura - hemolytic uremic syndrome. Curr Opin Hematol 1: 274
20. Tonato M, Mosconi AM and Martin C (1995) Safety profile of gemcitabine. Anticancer Drugs 6 (Suppl. 6): 27-32
21. Verwey J, De Vries J and Pinedo HM (1987) Mitomycin C-induced renal toxicity, a dose-dependent side effect? Eur J Cancer 23: 195
22. Zeigler ZR, Rosenfeld CS, Andrews III DF, Nemunaìtís J, Raymond JM, Shadduck RK, Kramer RE, Gryn JF, Rintels PB, Besa EC and George IN (1996) Plasma von Willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant-associated microangiopathy (BMT-TM). Am J Hematol 53: 213-220